- ￥473 - 5200
- MedChemExpress(MCE)
- 美国
- HY-B1831A
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
4°C, sealed storage, away from moisture
- 英文名：
LY333328 diphosphate
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
192564-14-0
- 规格：
10 mM * 1 mL/1 mg/2 mg/5 mg/10 mg/25 mg/50 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥3151.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥473.0 |
| 规格： | 2 mg | 产品价格： | ￥660.0 |
| 规格： | 5 mg | 产品价格： | ￥1250.0 |
| 规格： | 10 mg | 产品价格： | ￥2125.0 |
| 规格： | 25 mg | 产品价格： | ￥3600.0 |
| 规格： | 50 mg | 产品价格： | ￥5200.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Oritavancin diphosphate
CAS No. : 192564-14-0
MCE 国际站：Oritavancin diphosphate
产品活性：Oritavancin diphosphate (LY333328 diphosphate) 是一种具有口服活性的糖肽抗生素（antibiotic），对革兰氏阳性菌具有活性。Oritavancin diphosphate 对多重耐药性 S. pneumoniae 表现出抗菌（antibacterial）作用。Oritavancin diphosphate 抑制细胞壁合成，破坏膜电位。
研究领域：Anti-infection
作用靶点：Bacterial | Antibiotic
相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | Immunology/Inflammation Compound Library | FDA-Approved Drug Library | Drug Repurposing Compound Library | Antibacterial Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Antibiotics Library | EMA-Approved Drug Library | Non-steroidal Anti-Inflammatory Compound Library | Heterocyclic Compound Library | Off-patent Drug Library | Rapamycin | Cycloheximide | Chloroquine | Doxorubicin hydrochloride | Bafilomycin A1 | Dexamethasone | Puromycin dihydrochloride | Dimethyl sulfoxide | Staurosporine | Actinomycin D | G-418 disulfate | Etoposide | 5-Azacytidine | Cyclosporin A | Nigericin sodium salt | Brefeldin A | Estradiol | CCCP | Ionomycin | Resveratrol | Hygromycin B | Tunicamycin | Bleomycin sulfate | Mitomycin C | Everolimus | Doxycycline hyclate | Tacrolimus | Methotrexate | Wortmannin
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Treatment of Infections Caused by Resistant Staphylococcus aureus
-positive organisms at an advanced stage of clinical testing: ceptobiprole and three new glycopeptides with potent bactericidal activity, oritavancin, dalbavancin, and telavancin. Thus, there are currently many effective drugs to treat resistant S. aureus
Treatment of Infections Due to Resistant Staphylococcus aureus
with broad-spectrum activity against Gm-positive organisms that have reached the phase II and III stages of clinical testing that will hopefully be approved for clinical use in the upcoming years: oritavancin, dalbavancin, omadacycline, tedizolid
技术资料暂无技术资料 索取技术资料
